Daré Bioscience Receives $4M Grant for DARE-LARC1 Contraceptive Development

Daré Bioscience received a $4 million non-dilutive funding installment under its multi-year grant agreement to develop DARE-LARC1, a long-acting reversible contraceptive using the company's intelligent drug delivery system (DARE-IDDS) platform. This brings the total received to $41.8 million, out of a committed grant funding of up to $49 million. The funding will support nonclinical development, IND-enabling studies, and preparation for submission of an IND application to the FDA.

SAN DIEGO, Sep 12, 2025 — Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company focused on women's health, has received a $4 million non-dilutive funding installment under its multi-year grant agreement. This funding will support the development of DARE-LARC1, a long-acting reversible contraceptive (LARC) utilizing the company's intelligent drug delivery system (DARE-IDDS) platform.

The total funding received by Daré to date is approximately $41.8 million, out of a committed grant funding of up to $49 million. The funds will be used for nonclinical development, IND-enabling studies, and preparation for submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).

DARE-LARC1 is a preclinical-stage investigational contraceptive that uses a next-generation programmable drug delivery device to administer levonorgestrel, the active pharmaceutical ingredient in several FDA-approved birth control methods, for an extended period without daily effort. The DARE-IDDS platform has broader potential across various therapeutic areas, including obesity, diabetes, and other chronic conditions that require precise, programmable, and/or long-term dosing.

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, stated, "This funding milestone will help advance what we believe is one of the most promising smart drug delivery technologies in development today. With non-dilutive capital covering early development, we are not only progressing a novel contraceptive but also laying the foundation for a versatile, programmable drug delivery device platform across high-value therapeutic areas."

Daré is eligible for additional non-dilutive funding for the DARE-LARC1 program, up to approximately $7.1 million, contingent on achieving specified technical and other milestones. The company is also exploring strategic collaborations to expand the evaluation of the DARE-IDDS platform into additional therapeutic categories.

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders^[1] https://www.stocktitan.net/news/DARE/dare-bioscience-receives-4-million-non-dilutive-grant-installment-cdihmw4cpd9t.html